Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. IMVT

(IMVT)

NMS – Real Time Price. Currency in USD

23.98

-1.38 (-5.44%)

At close: Mar 27, 2026, 4:00 PM EDT

23.84

-0.14 (-0.56%)

After-hours: Mar 27, 2026, 6:31 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
23.98$
Day's range
23.95 - 25.56$
52-week range
12.72 - 29.25$
Volume
1 133 141
Average volume
1 510 690
Beta
1.26
EPS (TTM)
-2.68
PE ratio (TTM)
N/A
Market cap
4 880 701 602
Shares outstanding
203 532 177
Dividend yield
N/A
Next earnings date
2026-06-03
Sector
Healthcare
Industry
Biotechnology

About the company

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye... read more
CEO
Eric Venker
Country
United States
IPO Date
Employees
362
Fiscal Year End
April - March
Website
https://immunovant.com

Revenue Breakdown

No Data

Revenue breakdown data has not been calculated yet.

News

No Data

There are no news for this stock.

Chart: IMVT

Loading Chart...

Overall Score

2.8 / 1028%
Financial Strength
8.2
Profitability
1
Effectiveness
1
Growth
5.4
Forecast
2.9
Valuation
1.6

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio15.746.0510
Quick ratio15.745.6310
Debt to Equity0.000.3010
Debt to Assets0.001.0410
Interest coverageN/A-16.911.0
Weighted average score8.2

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2021202220232024TTM
Total RevenueN/AN/AN/AN/AN/A
Gross Profit-1M-1M-231K-377K-422K
Operating Income-156M-208M-270M-438M-487M
Net Income-157M-211M-259M-414M-464M
EBITDA-155M-207M-270M-438M-487M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %N/A-11.731.0
Operating margin %N/A-24.601.0
Net margin %N/A-172.201.0
EBITDA margin %N/A-201.271.0
Cash flow margin %N/A-156.391.0
Weighted average score1.0

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-69.11-57.97
1.0
ROE-76.33-63.56
1.0
ROIC-76.33-42.57
1.0
ROCE-18.48-71.10
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarterN/A6.343.0
Next quarterN/A10.134.0
Current yearN/A3.542.5
Next yearN/A2.292.0
Weighted average score2.9

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q99912.5416.449.948.3
Y/Y9990.4419.748.26.8
3y average999-39.02-24.89-55.493.3
5y average999-44.94-14.21-50.053.3
Weighted average score5.4

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/EN/A-5.25
1.0
PEG (5yr expected)N/A0.27
1.0
P/SN/A64.66
1.0
P/B4.742.96
3.2
Weighted average score1.6

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price23.98$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$23.98

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Cash reserves $994.5M barely cover the upcoming debt maturities $0.0

Total current assets $1.0B exceed Total current liabilities $66.3M, highlighting excellent liquidity

Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Negative free cash flow -$92.3M limits the company's ability to reinvest or pay down debt